Holen Sie sich die Stockscreener-App
25.10
1.50%
0.37
Handel nachbörslich:
24.96
-0.14
-0.56%
Schlusskurs vom Vortag:
$24.73
Offen:
$24.75
24-Stunden-Volumen:
18.68M
Relative Volume:
1.97
Marktkapitalisierung:
$9.77B
Einnahmen:
$3.14B
Nettoeinkommen (Verlust:
$-3.36B
KGV:
-2.8751
EPS:
-8.73
Netto-Cashflow:
$-4.03B
1W Leistung:
-6.66%
1M Leistung:
-26.50%
6M Leistung:
-19.27%
1J Leistung:
-68.22%
1-Tages-Spanne:
$24.28
$25.64
1-Wochen-Bereich:
$24.28
$27.80
52-Wochen-Spanne:
$23.15
$80.56
Moderna Inc Stock (MRNA) Company Profile
Firmenname
Moderna Inc
Sektor
Branche
Telefon
(617) 714-6500
Adresse
325 BINNEY STREET, CAMBRIDGE
Vergleichen Sie MRNA mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
MRNA
Moderna Inc
|
25.10 | 9.62B | 3.14B | -3.36B | -4.03B | -8.73 |
|
VRTX
Vertex Pharmaceuticals Inc
|
389.08 | 99.27B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
586.96 | 62.28B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
454.18 | 59.14B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
707.96 | 43.34B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
300.14 | 36.72B | 3.81B | -644.79M | -669.77M | -6.24 |
Moderna Inc Stock (MRNA) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-03-13 | Eingeleitet | Citigroup | Neutral |
| 2025-02-18 | Herabstufung | Barclays | Overweight → Equal Weight |
| 2025-01-29 | Herabstufung | Goldman | Buy → Neutral |
| 2024-12-18 | Herabstufung | Argus | Buy → Hold |
| 2024-12-10 | Fortgesetzt | BofA Securities | Underperform |
| 2024-11-19 | Eingeleitet | Berenberg | Hold |
| 2024-11-18 | Hochstufung | HSBC Securities | Hold → Buy |
| 2024-11-15 | Eingeleitet | Wolfe Research | Underperform |
| 2024-10-17 | Eingeleitet | Bernstein | Mkt Perform |
| 2024-09-13 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2024-09-13 | Herabstufung | Jefferies | Buy → Hold |
| 2024-09-13 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2024-08-28 | Hochstufung | HSBC Securities | Reduce → Hold |
| 2024-08-07 | Hochstufung | Deutsche Bank | Sell → Hold |
| 2024-08-05 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2024-02-26 | Herabstufung | HSBC Securities | Hold → Reduce |
| 2024-01-02 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2023-11-29 | Eingeleitet | Canaccord Genuity | Hold |
| 2023-11-03 | Hochstufung | HSBC Securities | Reduce → Hold |
| 2023-11-02 | Herabstufung | Deutsche Bank | Hold → Sell |
| 2023-08-04 | Herabstufung | TD Cowen | Outperform → Market Perform |
| 2023-08-03 | Herabstufung | Deutsche Bank | Buy → Hold |
| 2023-07-24 | Eingeleitet | William Blair | Mkt Perform |
| 2023-07-14 | Eingeleitet | HSBC Securities | Reduce |
| 2023-06-26 | Hochstufung | UBS | Neutral → Buy |
| 2023-04-26 | Eingeleitet | Guggenheim | Neutral |
| 2023-03-13 | Hochstufung | TD Cowen | Market Perform → Outperform |
| 2023-03-02 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2023-02-24 | Herabstufung | SVB Securities | Market Perform → Underperform |
| 2022-12-19 | Hochstufung | Jefferies | Hold → Buy |
| 2022-12-14 | Herabstufung | Chardan Capital Markets | Buy → Neutral |
| 2022-10-21 | Hochstufung | SVB Leerink | Underperform → Mkt Perform |
| 2022-09-08 | Hochstufung | Deutsche Bank | Hold → Buy |
| 2022-02-01 | Hochstufung | Redburn | Sell → Neutral |
| 2022-01-26 | Hochstufung | Deutsche Bank | Sell → Hold |
| 2022-01-21 | Hochstufung | BofA Securities | Underperform → Neutral |
| 2022-01-21 | Eingeleitet | UBS | Neutral |
| 2021-12-07 | Eingeleitet | Cowen | Market Perform |
| 2021-11-09 | Eingeleitet | Wolfe Research | Outperform |
| 2021-10-22 | Eingeleitet | Deutsche Bank | Sell |
| 2021-10-15 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2021-08-06 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2021-08-06 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2021-07-15 | Bestätigt | Jefferies | Hold |
| 2021-02-01 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2020-12-16 | Herabstufung | Jefferies | Buy → Hold |
| 2020-12-16 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2020-12-09 | Herabstufung | Needham | Buy → Hold |
| 2020-11-23 | Eingeleitet | Wells Fargo | Equal Weight |
| 2020-11-17 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
| 2020-09-08 | Herabstufung | SVB Leerink | Mkt Perform → Underperform |
| 2020-07-23 | Eingeleitet | SVB Leerink | Mkt Perform |
| 2020-07-20 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2020-07-13 | Eingeleitet | Jefferies | Buy |
| 2020-06-30 | Eingeleitet | Argus | Buy |
| 2020-06-08 | Eingeleitet | Barclays | Overweight |
| 2020-04-30 | Eingeleitet | BMO Capital Markets | Outperform |
| 2020-03-05 | Herabstufung | BofA/Merrill | Buy → Neutral |
| 2019-12-03 | Fortgesetzt | BofA/Merrill | Buy |
| 2019-10-25 | Eingeleitet | ROTH Capital | Buy |
| 2019-04-05 | Eingeleitet | Chardan Capital Markets | Buy |
Alle ansehen
Moderna Inc Aktie (MRNA) Neueste Nachrichten
Aberdeen Group plc Decreases Position in Moderna, Inc. $MRNA - MarketBeat
Jump Financial LLC Has $25.58 Million Stock Position in Moderna, Inc. $MRNA - MarketBeat
Wellington Management Group LLP Cuts Stake in Moderna, Inc. $MRNA - MarketBeat
Credit Agricole S A Decreases Position in Moderna, Inc. $MRNA - MarketBeat
Cresset Asset Management LLC Buys Shares of 18,420 Moderna, Inc. $MRNA - MarketBeat
Candriam S.C.A. Decreases Position in Moderna, Inc. $MRNA - MarketBeat
Moderna, Inc. $MRNA Shares Sold by Russell Investments Group Ltd. - MarketBeat
Korea Investment CORP Boosts Stake in Moderna, Inc. $MRNA - MarketBeat
FDA approves COVID-19 vaccines only for ‘high risk’ people - Yahoo News Australia
Which COVID-19 vaccines are FDA approved in US? - Reuters
FDA Curbs Covid Shot Access as RFK Jr. Takes Tougher Stance - Bloomberg.com
Moderna to Present at Upcoming Conferences in September 2025 - Canton Repository
RFK Jr. Rescinds Emergency Authorizations For COVID-19 Vaccines - Benzinga
FDA approves updated COVID boosters, but narrows use - BioPharma Dive
Why Moderna (MRNA) Stock Is Up Today - TradingView
Moderna Receives US FDA Approval for Updated COVID-19 Vaccines Targeting the LP.8.1 Variant - MarketScreener
Moderna Receives U.S. FDA Approval for Updated COVID-19 Vaccines Targeting LP.8.1 Variant of SARS-CoV-2 - The Joplin Globe
Latest COVID Defense: Moderna's New LP.8.1 Vaccines Cover 4M Annual Cases, FDA Gives Green Light - Stock Titan
FDA approves updated Covid vaccines, including mRNA shots from Pfizer, Moderna - Endpoints News
FDA authorizes updated Covid-19 shots, but with restrictions - Seeking Alpha
F.D.A. Approves Covid Shots With New Restrictions - The New York Times
Moderna (NASDAQ:MRNA) Stock Price Down 5.2% Following Analyst Downgrade - MarketBeat
Moderna Challenged on Bid to Shift Covid-Shot Patent Costs to US - Bloomberg Law News
Stock Analysis | Moderna OutlookA Deep Dive Into Mixed Signals and Key Catalysts - AInvest
Moderna, Inc. $MRNA Shares Sold by Groupe la Francaise - MarketBeat
Moderna, Inc. $MRNA Shares Bought by Northern Trust Corp - MarketBeat
Moderna, Inc. $MRNA Shares Sold by State of New Jersey Common Pension Fund D - MarketBeat
Banco Bilbao Vizcaya Argentaria S.A. Sells 183,308 Shares of Moderna, Inc. $MRNA - MarketBeat
Developing predictive dashboards with Moderna Inc. dataMarket Volume Report & AI Optimized Trading Strategy Guides - Newser
UK Court of Appeal Confirms Moderna’s EP’949 Patent is Valid and Infringed by Pfizer/BioNTech - Corpus Christi Caller-Times
Short interest data insights for Moderna Inc.July 2025 Opening Moves & Entry and Exit Point Strategies - Newser
Will breakout in Moderna Inc. lead to full recovery2025 Support & Resistance & Growth Focused Investment Plans - Newser
Moderna Inc. stock retracement – recovery analysis2025 Trading Recap & Intraday High Probability Setup Alerts - Newser
Moderna, Inc. shares fall 2.37% intraday amid political uncertainty and Fed independence concerns. - AInvest
Market reaction to Moderna Inc.’s recent newsDollar Strength & Long-Term Growth Portfolio Plans - Newser
Untreated Metastatic or Unresectable Melanoma Clinical Trial Pipeline Expands as 10+ Companies Driving Innovation in Oncology Therapeutics Space | DelveInsight - GlobeNewswire Inc.
Using RSI to spot recovery in Moderna Inc.July 2025 Opening Moves & Pattern Based Trade Signal System - Newser
Moderna, Inc. $MRNA Stock Position Lowered by Hsbc Holdings PLC - MarketBeat
Moderna stock falls, Pfizer dips on COVID vaccine ban speculation - Investing.com
Contra Guys: This revolutionary biotech pioneer has joined our watchlist - The Globe and Mail
Moderna Inc. stock momentum explainedRisk Management & Free High Accuracy Swing Entry Alerts - Newser
What’s the recovery path for long term holders of Moderna Inc.2025 Macro Impact & Low Risk Entry Point Tips - Newser
Trump Administration Plans To Pull COVID-19 Vaccines Off Market 'Within Months' - Benzinga
Trump administration could ban COVID-19 jabs 'within months': Daily Beast (MRNA:NASDAQ) - Seeking Alpha
Covid vaccine critic tapped to lead CDC advisory committee on shots - Seeking Alpha
Moderna’s updated Covid-19 vaccine gets Canadian approval - Yahoo Finance
Northwest & Ethical Investments L.P. Sells 21,004 Shares of Moderna, Inc. $MRNA - MarketBeat
Moderna, Inc. $MRNA Shares Purchased by BNP PARIBAS ASSET MANAGEMENT Holding S.A. - MarketBeat
Moderna, Inc. (NASDAQ:MRNA) Receives $43.59 Average Target Price from Analysts - MarketBeat
Moderna, Inc. (MRNA) Down 35% YTD. Here Is Why - MSN
Freestone Capital Holdings LLC Takes Position in Moderna, Inc. $MRNA - MarketBeat
Finanzdaten der Moderna Inc-Aktie (MRNA)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.98%
8.06%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):